

Updated (2023–2024 Formula) COVID-19 Vaccine

Interim 2023-2024 COVID-19 Immunization Schedule
for Persons 6 Months of Age and Older



The following tables provide COVID-19 vaccination schedules based on age, health status, and product. For detailed guidance see [Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC](#).

USCISclinic.com

Table 1a. For people who are **NOT** moderately or severely immunocompromised*

2023-24 Moderna COVID-19 Vaccine			
Vaccine type: mRNA - Do NOT use any previously available Moderna COVID-19 vaccine products.			
Age	COVID-19 Vaccination History [†] (regardless of COVID-19 vaccine formula)	2023-24 Vaccine Schedule	Administer
6 months through 4 years	Unvaccinated (0 doses)	Give a 2-dose initial series. Administer: <ul style="list-style-type: none"> • Dose 1 now • Dose 2 at least 4–8 weeks after Dose 1[‡] 	0.25 mL/25 µg
	1 previous dose of any Moderna COVID-19 Vaccine (Dose 1) [§]	Give Dose 2 at least 4–8 weeks after the last dose [‡]	From single-dose vial with dark blue cap and green label
	2 or more doses Moderna COVID-19 Vaccine, NOT including at least 1 dose of 2023–24 vaccine ^{§¶}	Give 1 dose at least 8 weeks (2 months) after the last dose	Intramuscular (IM) injection
	2 or more doses Moderna COVID-19 Vaccine, INCLUDING at least 1 dose of 2023–24 vaccine ^{§¶}	No further doses are indicated	
5 through 11 years	Unvaccinated (0 doses)	Give 1 dose now	0.25 mL/25 µg
	Any number of previous doses COVID-19 vaccine, NOT including at least 1 dose of 2023–24 vaccine	Give 1 dose at least 8 weeks (2 months) after the last dose	From single-dose vial with dark blue cap and green label Intramuscular (IM) injection
	Any number of previous doses COVID-19 vaccine, INCLUDING at least 1 dose of 2023–24 vaccine	No further doses are indicated	
12 years and older	Unvaccinated (0 doses)	Give 1 dose now	0.5 mL/50 µg
	Any number of previous doses COVID-19 vaccine, NOT including at least 1 dose of 2023–24 vaccine	Give 1 dose at least 8 weeks (2 months) after the previous dose	From single-dose vial with dark blue cap and blue label Intramuscular (IM) injection
	Any number of previous doses COVID-19 vaccine, INCLUDING at least 1 dose of 2023–24 vaccine	No further doses are indicated	

* Persons with a recent SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic).
[†] COVID-19 vaccination history refers to previous receipt of dose(s) of original monovalent (ancestral) mRNA, bivalent mRNA vaccine, Updated (2023–2024 Formula), or a combination of the three, unless otherwise specified.
[‡] An 8-week interval between the first and second COVID-19 vaccine (Moderna, Novavax, and Pfizer-BioNTech) doses might be optimal for some people as it might reduce the small risk of myocarditis and pericarditis associated with these vaccines.
[§] People who are recommended to receive a multidose mRNA series for initial vaccination (i.e., children ages 6 months–4 years and people who are moderately or severely immunocompromised) should receive all doses from the same manufacturer. However, in the following exceptional situations a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available, the person would otherwise not complete the vaccination series, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication.
[¶] For children who have received 1 Moderna and 1 Pfizer-BioNTech vaccines of any formulation, follow a 3-dose schedule. A third dose of either Moderna vaccine or Pfizer-BioNTech vaccine should be administered at least 8 weeks after the second dose.

Updated (2023–2024 Formula) COVID-19 Vaccine

Interim 2023–2024 COVID-19 Immunization Schedule
for Persons 6 Months of Age and Older



Table 1b. For people who are **NOT** moderately or severely immunocompromised*

2023–24 Pfizer-BioNTech COVID-19 Vaccine

Vaccine type: mRNA - Do **NOT** use any previously available Pfizer-BioNTech COVID-19 vaccine products.

Age	COVID-19 Vaccination History [†] (regardless of COVID-19 vaccine formula)	2023–24 Vaccine Schedule	Administer
6 months through 4 years	Unvaccinated (0 doses)	Give a 3-dose initial series. Administer: <ul style="list-style-type: none"> • Dose 1 now • Dose 2 at least 3–8 weeks after Dose 1[‡] • Dose 3 at least 8 weeks (2 months) after Dose 2 	0.3 mL/3 μ g From yellow-capped vial with yellow label Intramuscular (IM) injection
	1 previous dose of any Pfizer-BioNTech COVID-19 Vaccine (Dose 1) [§]	Complete series. Administer: <ul style="list-style-type: none"> • Dose 2 at least 3–8 weeks after Dose 1[‡] • Dose 3 at least 8 weeks (2 months) after Dose 2 	
	2 doses of any Pfizer-BioNTech COVID-19 Vaccine (Doses 1 and 2) [¶]	Complete series. Administer: <ul style="list-style-type: none"> • Dose 3 at least 8 weeks (2 months) after Dose 2 	
	3 or more doses Pfizer-BioNTech COVID-19 Vaccine, NOT including at least 1 dose of 2023–24 COVID-19 vaccine [§]	Give 1 dose at least 8 weeks (2 months) after the last dose	
	3 or more doses Pfizer-BioNTech COVID-19 Vaccine, INCLUDING at least 1 dose of 2023–24 COVID-19 vaccine [§]	No further doses are indicated	
5 through 11 years	Unvaccinated (0 doses)	Give 1 dose now	0.3 mL/10 μ g From blue-capped vial with blue label Intramuscular (IM) injection
	Any number of previous doses COVID-19 vaccine, NOT including at least 1 dose of 2023–24 COVID-19 vaccine	Give 1 dose at least 8 weeks (2 months) after the last dose	
	Any number of previous doses COVID-19 vaccine, INCLUDING at least 1 dose of 2023–24 COVID-19 vaccine	No further doses are indicated	
12 years and older	Unvaccinated (0 doses)	Give 1 dose now	0.3 mL/30 μ g From gray-capped vial with gray label or manufacturer-filled syringe with gray box on label Intramuscular (IM) injection
	Any number of previous doses COVID-19 vaccine, NOT including at least 1 dose of 2023–24 COVID-19 vaccine	Give 1 dose at least 8 weeks (2 months) after the last dose	
	Any number of previous doses COVID-19 vaccine, INCLUDING at least 1 dose of 2023–24 COVID-19 vaccine	No further doses are indicated	

* Persons with a recent SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic).

[†] COVID-19 vaccination history refers to previous receipt of dose(s) of original monovalent (ancestral) mRNA, bivalent mRNA vaccine, Updated (2023–2024 Formula), or a combination of the three, unless otherwise specified.

[‡] An 8-week interval between the first and second COVID-19 vaccine (Moderna, Novavax, and Pfizer-BioNTech) doses might be optimal for some people as it might reduce the small risk of myocarditis and pericarditis associated with these vaccines.

[§] People who are recommended to receive a multidose mRNA series for initial vaccination (i.e., children ages 6 months–4 years and people who are moderately or severely immunocompromised) should receive all doses from the same manufacturer. However, in the following exceptional situations a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available, the person would otherwise not complete the vaccination series, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication.

[¶] For children who have received 1 Moderna and 1 Pfizer-BioNTech vaccines of any formulation, follow a 3-dose schedule. A third dose of either Moderna vaccine or Pfizer-BioNTech vaccine should be administered at least 8 weeks after the second dose.

Updated (2023–2024 Formula) COVID-19 Vaccine

Interim 2023–2024 COVID-19 Immunization Schedule
for Persons 6 Months of Age and Older



Table 2a. For people who **ARE** moderately or severely immunocompromised

2023–24 Moderna COVID-19 Vaccine			
Vaccine type: mRNA - Do NOT use any previously available Moderna COVID-19 vaccine products.			
Age	COVID-19 Vaccination History* (regardless of COVID-19 vaccine formula)	2023–24 Vaccine Schedule	Administer
6 months through 4 years	Unvaccinated (0 doses)	Give a 3-dose initial series. Administer: <ul style="list-style-type: none"> • Dose 1 now • Dose 2 at least 4 weeks after Dose 1 • Dose 3 at least 4 weeks after Dose 2 	0.25 mL/25 µg From single-dose vial with dark blue cap and green label Intramuscular (IM) injection
	1 previous dose of any Moderna COVID-19 Vaccine (Dose 1) [†]	Complete series. Administer: <ul style="list-style-type: none"> • Dose 2 at least 4 weeks after Dose 1 • Dose 3 at least 4 weeks after Dose 2 	
	2 doses of any Moderna COVID-19 Vaccine (Doses 1 and 2) ^{†‡}	Complete series. Administer: <ul style="list-style-type: none"> • Dose 3 at least 4 weeks after Dose 2 	
	3 or more doses of Moderna COVID-19 Vaccine, NOT including at least 1 dose of 2023–24 COVID-19 vaccine [†]	Give 1 dose at least 8 weeks (2 months) after the previous dose	
	3 or more doses of Moderna COVID-19 Vaccine, INCLUDING at least 1 dose of 2023–24 COVID-19 vaccine [†]	People who are moderately or severely immunocompromised have the option to receive 1 additional dose at least 8 weeks (2 months) following the last recommended dose. Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 8 weeks (2 months) after the last COVID-19 vaccine dose.	
5 through 11 years	Unvaccinated (0 doses)	Give a 3-dose initial series. Administer: <ul style="list-style-type: none"> • Dose 1 now • Dose 2 at least 4 weeks after Dose 1 • Dose 3 at least 4 weeks after Dose 2 	0.25 mL/25 µg From single-dose vial with dark blue cap and green label Intramuscular (IM) injection
	1 previous dose of any Moderna COVID-19 Vaccine (Dose 1) [†]	Complete series. Administer: <ul style="list-style-type: none"> • Dose 2 at least 4 weeks after Dose 1 • Dose 3 at least 4 weeks after Dose 2 	
	2 doses of any Moderna COVID-19 Vaccine (Doses 1 and 2) [†]	Complete series. Administer: <ul style="list-style-type: none"> • Dose 3 at least 4 weeks after Dose 2 	
	3 or more doses of Moderna COVID-19 Vaccine, NOT including at least 1 dose of 2023–24 COVID-19 vaccine [†]	Give 1 dose at least 8 weeks (2 months) after the last dose	
	3 or more doses of Moderna COVID-19 Vaccine, INCLUDING at least 1 dose of 2023–24 COVID-19 vaccine [†]	People who are moderately or severely immunocompromised have the option to receive 1 additional dose at least 8 weeks (2 months) following the last recommended dose. Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 8 weeks (2 months) after the last COVID-19 vaccine dose.	

* COVID-19 vaccination history refers to previous receipt of dose(s) of original monovalent (ancestral) mRNA, bivalent mRNA vaccine, Updated (2023–2024 Formula), or a combination of the three, unless otherwise specified.

† People who are recommended to receive a multidose mRNA series for initial vaccination (i.e., children ages 6 months–4 years and people who are moderately or severely immunocompromised) should receive all doses from the same manufacturer. However, in the following exceptional situations a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available, the person would otherwise not complete the vaccination series, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication.

‡ For children who have received 1 Moderna and 1 Pfizer-BioNTech vaccines of any formulation, follow a 3-dose schedule. A third dose of either Moderna vaccine or Pfizer-BioNTech vaccine should be administered at least 8 weeks after the second dose.

Updated (2023–2024 Formula) COVID-19 Vaccine

Interim 2023-2024 COVID-19 Immunization Schedule
for Persons 6 Months of Age and Older



Table 2a. For people who **ARE** moderately or severely immunocompromised *Continued*

2023-24 Moderna COVID-19 Vaccine - CONTINUED			
Vaccine type: mRNA - Do NOT use any previously available Moderna COVID-19 vaccine products.			
Age	COVID-19 Vaccination History* (regardless of COVID-19 vaccine formula)	2023-24 Vaccine Schedule	Administer
12 years and older	Unvaccinated 0 doses	Give a 3-dose initial series. Administer: <ul style="list-style-type: none"> • Dose 1 now • Dose 2 at least 4 weeks after Dose 1 • Dose 3 at least 4 weeks after Dose 2 	0.5 mL/50 µg From single-dose vial with dark blue cap and blue label Intramuscular (IM) injection
	1 previous dose of any Moderna COVID-19 Vaccine (Dose 1) [†]	Complete series. Administer: <ul style="list-style-type: none"> • Dose 2 at least 4 weeks after Dose 1 • Dose 3 at least 4 weeks after Dose 2 	
	2 doses of any Moderna COVID-19 Vaccine (Doses 1 and 2) [†]	Complete series. Administer: <ul style="list-style-type: none"> • Dose 3 at least 4 weeks after Dose 2 	
	3 or more doses of Moderna COVID-19 Vaccine, NOT including at least 1 dose of 2023–24 COVID-19 vaccine [†]	Give 1 dose at least 8 weeks (2 months) after the previous dose	
	3 or more doses of Moderna COVID-19 Vaccine, INCLUDING at least 1 dose of 2023–24 COVID-19 vaccine [†]	People who are moderately or severely immunocompromised have the option to receive 1 additional dose at least 8 weeks (2 months) following the last recommended dose. Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 8 weeks (2 months) after the last COVID-19 vaccine dose.	

* COVID-19 vaccination history refers to previous receipt of dose(s) of original monovalent (ancestral) mRNA, bivalent mRNA vaccine, Updated (2023–2024 Formula), or a combination of the three, unless otherwise specified.

† People who are recommended to receive a multidose mRNA series for initial vaccination (i.e., children ages 6 months–4 years and people who are moderately or severely immunocompromised) should receive all doses from the same manufacturer. However, in the following exceptional situations a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available, the person would otherwise not complete the vaccination series, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication.

More Info Visit > [USCISclinic.com](https://www.uscisclinic.com)

Neema Malhotra, MD
USCIS Civil Surgeon

(408) 684-8600

98 S Abel St, Milpitas CA 95035
2730 Union Ave, #B, San Jose CA 95124

Updated (2023–2024 Formula) COVID-19 Vaccine

Interim 2023–2024 COVID-19 Immunization Schedule
for Persons 6 Months of Age and Older



Table 2b. For people who **ARE** moderately or severely immunocompromised

2023–24 Pfizer-BioNTech COVID-19 Vaccine			
Vaccine type: mRNA - Do NOT use any previously available Pfizer-BioNTech COVID-19 vaccine products.			
Age	COVID-19 Vaccination History* (regardless of COVID-19 vaccine formula)	2023–24 Vaccine Schedule	Administer
6 months through 4 years	Unvaccinated: (0 doses)	Give a 3-dose initial series. Administer: <ul style="list-style-type: none"> • Dose 1 now • Dose 2 at least 3 weeks after Dose 1 • Dose 3 at least 8 weeks (2 months) after Dose 2 	0.3 mL/3 μ g From yellow-capped vial with yellow label Intramuscular (IM) injection
	1 previous dose of any Pfizer-BioNTech COVID-19 Vaccine (Dose 1) [†]	Complete series. Administer: <ul style="list-style-type: none"> • Dose 2 at least 3 weeks after Dose 1 • Dose 3 at least 8 weeks (2 months) after Dose 2 	
	2 doses of any Pfizer-BioNTech COVID-19 Vaccine (Doses 1 and 2) ^{††}	Complete series. Administer: <ul style="list-style-type: none"> • Dose 3 at least 8 weeks (2 months) after Dose 2 	
	3 or more doses of Pfizer-BioNTech COVID-19 Vaccine, NOT including at least 1 dose of 2023–24 COVID-19 vaccine [†]	Give 1 dose at least 8 weeks (2 months) after the previous dose	
	3 or more doses of Pfizer-BioNTech COVID-19 Vaccine, INCLUDING at least 1 dose of 2023–24 COVID-19 vaccine [†]	People who are moderately or severely immunocompromised have the option to receive 1 additional dose at least 8 weeks (2 months) following the last recommended dose. Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 8 weeks (2 months) after the last COVID-19 vaccine dose.	
5 through 11 years	Unvaccinated: (0 doses)	Give a 3-dose initial series. Administer: <ul style="list-style-type: none"> • Dose 1 now • Dose 2 at least 3 weeks after Dose 1 • Dose 3 at least 4 weeks after Dose 2 	0.3 mL/10 μ g From blue-capped vial with blue label Intramuscular (IM) injection
	1 previous dose of any Pfizer-BioNTech COVID-19 Vaccine (Dose 1) [†]	Complete series. Administer: <ul style="list-style-type: none"> • Dose 2 at least 3 weeks after Dose 1 • Dose 3 at least 4 weeks after Dose 2 	
	2 doses of any Pfizer-BioNTech COVID-19 Vaccine (Doses 1 and 2) [†]	Complete series. Administer: <ul style="list-style-type: none"> • Dose 3 at least 4 weeks after Dose 2 	
	3 or more doses of Pfizer-BioNTech COVID-19 Vaccine, NOT including at least 1 dose of 2023–24 COVID-19 vaccine [†]	Give 1 dose at least 8 weeks (2 months) after the last dose	
	3 or more doses of Pfizer-BioNTech COVID-19 Vaccine, INCLUDING at least 1 dose of 2023–24 COVID-19 vaccine [†]	People who are moderately or severely immunocompromised have the option to receive 1 additional dose at least 8 weeks (2 months) following the last recommended dose. Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 8 weeks (2 months) after the last COVID-19 vaccine dose.	

* COVID-19 vaccination history refers to previous receipt of dose(s) of original monovalent (ancestral) mRNA, bivalent mRNA vaccine, Updated (2023–2024 Formula), or a combination of the three, unless otherwise specified.

† People who are recommended to receive a multidose mRNA series for initial vaccination (i.e., children ages 6 months–4 years and people who are moderately or severely immunocompromised) should receive all doses from the same manufacturer. However, in the following exceptional situations a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available, the person would otherwise not complete the vaccination series, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication.

‡ For children who have received 1 Moderna and 1 Pfizer-BioNTech vaccines of any formulation, follow a 3-dose schedule. A third dose of either Pfizer-BioNTech vaccine or Pfizer-BioNTech vaccine should be administered at least 8 weeks after the second dose.

Updated (2023–2024 Formula) COVID-19 Vaccine

Interim 2023-2024 COVID-19 Immunization Schedule
for Persons 6 Months of Age and Older



Table 2b. For people who **ARE** moderately or severely immunocompromised *Continued*

2023-24 Pfizer-BioNTech COVID-19 Vaccine - CONTINUED			
Vaccine type: mRNA - Do NOT use any previously available Pfizer-BioNTech COVID-19 vaccine products.			
Age	COVID-19 Vaccination History* (regardless of COVID-19 vaccine formula)	2023-24 Vaccine Schedule	Administer
12 years and older	Unvaccinated: 0 doses	Give a 3-dose initial series. Administer: <ul style="list-style-type: none"> • Dose 1 now • Dose 2 at least 3 weeks after Dose 1 • Dose 3 at least 4 weeks after Dose 2 	0.3 mL/30 µg From gray-capped vial with gray label or manufacturer-filled syringe with gray box on label Intramuscular (IM) injection
	1 previous dose of any Pfizer-BioNTech COVID-19 Vaccine (Dose 1) [†]	Complete series. Administer: <ul style="list-style-type: none"> • Dose 2 at least 3 weeks after Dose 1 • Dose 3 at least 4 weeks after Dose 2 	
	2 doses of any Pfizer-BioNTech COVID-19 Vaccine (Doses 1 and 2) [†]	Complete series. Administer: <ul style="list-style-type: none"> • Dose 3 at least 4 weeks after Dose 2 	
	3 or more doses of Pfizer-BioNTech COVID-19 Vaccine, NOT including at least 1 dose of 2023–24 COVID-19 vaccine [†]	Give 1 dose at least 8 weeks (2 months) after the last dose	
	3 or more doses of Pfizer-BioNTech COVID-19 Vaccine, INCLUDING at least 1 dose of 2023–24 COVID-19 vaccine [†]	People who are moderately or severely immunocompromised have the option to receive 1 additional dose at least 8 weeks (2 months) following the last recommended dose. Further additional dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 8 weeks (2 months) after the last COVID-19 vaccine dose.	

* COVID-19 vaccination history refers to previous receipt of dose(s) of original monovalent (ancestral) mRNA, bivalent mRNA vaccine, Updated (2023–2024 Formula), or a combination of the three, unless otherwise specified.

† People who are recommended to receive a multidose mRNA series for initial vaccination (i.e., children ages 6 months–4 years and people who are moderately or severely immunocompromised) should receive all doses from the same manufacturer. However, in the following exceptional situations a different age-appropriate COVID-19 vaccine product may be administered: the same vaccine is not available, the person would otherwise not complete the vaccination series, or the person starts but is unable to complete a vaccination series with the same vaccine due to a contraindication.

Neema Malhotra, MD

USCIS Civil Surgeon

(408) 684-8600

**98 S Abel St, Milpitas CA 95035
2730 Union Ave, #B, San Jose CA 95124**

USCISclinic.com